N@N

Human Genome Sciences Appoints Allan Baxter, Ph.D., to Its Board of Directors

_{//health-fitness.news-articles.net/content/2011/ .. allan-baxter-ph-d-to-its-board-of-directors.html}
^{Published in Health and Fitness on Thursday, May 12th 2011 at 4:00 GMT by Market Wire}  

ROCKVILLE, Md.--([ BUSINESS WIRE ])--Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that Allan Baxter, Ph.D., former Senior Vice President, Medicines Development, GlaxoSmithKline (GSK), has been appointed to the HGS Board of Directors.

"Allan has a remarkable record of success in managing global portfolios of product candidates through all stages of research and development, and we look forward to benefiting from his insight and experience."

aAllan Baxter has had a long and distinguished career in drug discovery and development at one of the worlda™s leading pharmaceutical companies and we are honored to have him join our Board of Directors,a said H. Thomas Watkins, President and Chief Executive Officer, Human Genome Sciences. aAllan has a remarkable record of success in managing global portfolios of product candidates through all stages of research and development, and we look forward to benefiting from his insight and experience.a

Over the course of a 30-year career with GSK, Dr. Baxter created and led GSKa™s six Centres of Excellence for Drug Discovery. From 2006-2010, he served as Senior Vice President, Medicines Development, with worldwide responsibility for GSKa™s late-stage portfolio of investigational medicines from Phase 2 through regulatory approval and into lifecycle management. He previously served as Senior Vice President, Drug Discovery, from 2001-2006. Prior to that, Dr. Baxter advanced through a series of senior R&D leadership positions within Glaxo, Glaxo Wellcome and GSK.

Dr. Baxter received his B.Sc. degree with honors in chemistry from the University of Strathclyde, Glasgow, Scotland, and his Ph.D. in biochemistry from Glasgow University. He was awarded a D.Sc. honoris causae from the University of Glasgow in 2006 and a D.Sc. honoris causae from the University of Strathclyde in 2008. Dr. Baxter is a visiting Professor of the Institute of Biological and Life Sciences of the University of Glasgow. He serves as a non-executive Director of Vernalis (R&D) Ltd., a Founding Advisor of Ascletis, Chair of the Wellcome Trusta™s Seeding Drug Discovery Funding Committee, and Chair of the Board of Directors of the Stevenage Bioscience Catalyst.

ABOUT HUMAN GENOME SCIENCES

Human Genome Sciences exists to place new therapies into the hands of those battling serious disease.

For more information about HGS, please visit the Companya™s web site at [ www.hgsi.com ]. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to [ medinfo@hgsi.com ] or by calling HGS at (877) 822-8472.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners.